Michael Barbella, Managing Editor06.02.23
Electromedical Products International Inc. (EPI) has formed a Scientific Advisory Board (SAB) comprising leading clinicians and researchers in neurology, psychiatry and neurostimulation. The SAB will work closely with EPI’s leadership team to provide scientific and clinical input into the company’s clinical trials in non-invasive brain stimulation as well as potential expansion into additional therapeutic indications. The SAB will also advise Pulvinar Neuro, a wholly owned subsidiary of EPI, on the development of its neurotechnology portfolio.
"We are honored to collaborate with this group of leaders in neurostimulation. Their expertise will be valuable in advancing our mission to develop and grow our portfolio of non-invasive brain stimulation treatments to benefit patients," EPI President Brian Burke said.
The inaugural SAB members include:
Pulvinar Neuro is a neurotechnology company and a wholly owned subsidiary of EPI. Pulvinar Neuro is dedicated to supporting the research community with non-invasive brain stimulation research tools as well as the technical development of therapeutics to address some of the most pressing challenges in mental health.
EPI is a medical device company in non-invasive brain stimulation for psychiatric disorders and pain management. EPI manufactures the Alpha-Stim brand of patented devices that are U.S. Food and Drug Administration cleared to provide fast, safe, and effective treatment of anxiety and insomnia via cranial electrotherapy stimulation (CES) and pain via microcurrent electrical therapy (MET). Alpha-Stim is available in more than 50 countries worldwide and is available via prescription in the United States.
"We are honored to collaborate with this group of leaders in neurostimulation. Their expertise will be valuable in advancing our mission to develop and grow our portfolio of non-invasive brain stimulation treatments to benefit patients," EPI President Brian Burke said.
The inaugural SAB members include:
- Flavio Frohlich, Ph.D., chair—professor of Psychiatry, Cell Biology and Physiology, and Biomedical Engineering at the University of North Carolina at Chapel Hill and director, Carolina Center for Neurostimulation. Frohlich has deep expertise in neurotechnology development, translational non-invasive brain stimulation research, and clinical trials in psychiatry and neurology. He is a pioneer in the rational design of transcranial alternating current stimulation (tACS) for depression and chronic pain, has led the discovery of the mechanism of action of tACS, and is the inventor of closed-loop tACS licensed by EPI.
- Andrea Antal, Ph.D.—professor and Group Leader, Non-Invasive Brain Stimulation Laboratory, Department of Neurology at the University of Gottingen (Germany). Antal is an internationally recognized leader in transcranial direct current stimulation (tDCS) and tACS. She leads a research program to further develop tACS and its applications in areas including chronic pain and cognitive impairment in the elderly. Antal’s studies range from basic research on the optimization of stimulation parameters on the human cortex to clinical trials.
- Noah S. Philip, M.D.—professor of Psychiatry and Human Behavior, The Warren Alpert Medical School, Brown University. Philip combines seminal contributions to research in non-invasive brain stimulation with excellence in training and mentoring of the next generation of psychiatrists. In his research, Philip utilizes new and emerging technologies, such as transcranial magnetic stimulation, tDCS and focused ultrasound, to understand and treat serious mental health disorders, such as depression, anxiety disorders, and posttraumatic stress disorder.
Pulvinar Neuro is a neurotechnology company and a wholly owned subsidiary of EPI. Pulvinar Neuro is dedicated to supporting the research community with non-invasive brain stimulation research tools as well as the technical development of therapeutics to address some of the most pressing challenges in mental health.
EPI is a medical device company in non-invasive brain stimulation for psychiatric disorders and pain management. EPI manufactures the Alpha-Stim brand of patented devices that are U.S. Food and Drug Administration cleared to provide fast, safe, and effective treatment of anxiety and insomnia via cranial electrotherapy stimulation (CES) and pain via microcurrent electrical therapy (MET). Alpha-Stim is available in more than 50 countries worldwide and is available via prescription in the United States.